<span item_type="fundamental" item_id="ac3f6fd19ccfc2d9e0c743af63693016" counter_id="ST/US/IMDX" env="prod"></span><span item_type="announcement" item_id="581348744020099329" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 260 K, missing the estimate of USD 285 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.34, missing the estimate of USD -0.21.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -11.05 M.</p><p></p><h3>Segment Revenue</h3><p>Insight Molecular Diagnostics Inc. reported revenues of $260,000 in Q3 2025, derived from laboratory services performed at their clinical laboratory in Nashville.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></p><h3>Operational Metrics</h3><ul><li>Gross profit for Q3 2025 was $139,000, representing a 53.5% gross margin.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Operating expenses for Q3 2025 totaled $11.2 million, including $3.4 million in non-cash changes in the fair value of contingent consideration, $521,000 in non-cash stock-based compensation expenses, and $563,000 in non-cash depreciation and amortization expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Research and development expenses increased 18% sequentially to $3.9 million in Q3 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Sales and marketing expenses declined 5% sequentially to $1.4 million in Q3 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>General and administrative expenses declined 4% sequentially to $2.5 million in Q3 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Net loss for Q3 2025 was $10.9 million, or - $0.34 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash, cash equivalents, and restricted cash balance at the end of Q3 2025 was $20.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Net cash used in operating activities for Q3 2025 was - $4.6 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li><li>Capital expenditures for Q3 2025 were - $1.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company did not realize any kitted product revenue in Q3 2025 and does not expect material revenue from kitted product sales until regulatory clearance is achieved.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>Insight Molecular Diagnostics Inc. is on track to submit GraftAssureDx™ for FDA review by year-end and aims to have 20 transplant centers globally engaged with GraftAssure technology by the end of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span> The company anticipates rapid expansion beyond kidney into heart transplant testing and expects to surpass near-term financial objectives, generating sustained free cash flow and heading towards $100 million in annual high-margin revenue growing at a double-digit pace.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span> There could be delays to the timeline due to the federal government shutdown, but the company is still preparing for a mid-2026 product launch.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/ex99-1.htm"></span></p>

Insight Molecular Diagnostics | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 260 K